Abstract
Although the main cause of many neurodegenerative diseases is unknown, the glial reaction is considered to be a consequence of neuronal cell death in Alzheimers disease, Parkinsons disease, and Huntingtons disease. In Parkinsons disease, postmortem examination and experimental animal models exposed to neurotoxin reveals a dramatic loss of dopaminergic neurons in the substantia nigra associated with a massive astrogliosis and the presence of activated microglial cells. These glial cells can release deleterious compounds such as proinflammatory prostaglandins and cytokines, which may act by stimulating reactive oxygen species in glial cells, or which may exert a more direct effect on dopaminergic neurons by activating receptors that contain death domains involved in neuronal apoptosis. The anti-inflammatory drugs and the tetracycline derivative minocycline have been shown to reduce glial activation and protect the substantia nigra in an animal model of the disease. Inhibition of the glial reaction and the inflammatory processes may thus represent a therapeutic target to reduce neuronal degeneration in Parkinsons disease. Elucidation of molecular mechanisms underlying intracellular signal transductions of glial activation will provide promising means of controlling neuroinflammation and the subsequent neurodegeneration.
Keywords: Neurodegenerative diseases, neuroinflammation, microglia, astrocyte, Parkinson's disease, experimental animal model, minocycline, central nervous system, signal transduction
Current Signal Transduction Therapy
Title: Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Volume: 2 Issue: 1
Author(s): Dong-Kug Choi and Kyoungho Suk
Affiliation:
Keywords: Neurodegenerative diseases, neuroinflammation, microglia, astrocyte, Parkinson's disease, experimental animal model, minocycline, central nervous system, signal transduction
Abstract: Although the main cause of many neurodegenerative diseases is unknown, the glial reaction is considered to be a consequence of neuronal cell death in Alzheimers disease, Parkinsons disease, and Huntingtons disease. In Parkinsons disease, postmortem examination and experimental animal models exposed to neurotoxin reveals a dramatic loss of dopaminergic neurons in the substantia nigra associated with a massive astrogliosis and the presence of activated microglial cells. These glial cells can release deleterious compounds such as proinflammatory prostaglandins and cytokines, which may act by stimulating reactive oxygen species in glial cells, or which may exert a more direct effect on dopaminergic neurons by activating receptors that contain death domains involved in neuronal apoptosis. The anti-inflammatory drugs and the tetracycline derivative minocycline have been shown to reduce glial activation and protect the substantia nigra in an animal model of the disease. Inhibition of the glial reaction and the inflammatory processes may thus represent a therapeutic target to reduce neuronal degeneration in Parkinsons disease. Elucidation of molecular mechanisms underlying intracellular signal transductions of glial activation will provide promising means of controlling neuroinflammation and the subsequent neurodegeneration.
Export Options
About this article
Cite this article as:
Choi Dong-Kug and Suk Kyoungho, Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target, Current Signal Transduction Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157436207779317146
DOI https://dx.doi.org/10.2174/157436207779317146 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews Gauging Reactive Metabolites in Drug-Induced Toxicity
Current Medicinal Chemistry Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Recent Advances in the Treatment of Interstitial Lung Disease in Patients with Polymyositis/Dermatomyositis
Endocrine, Metabolic & Immune Disorders - Drug Targets Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design The Therapeutic Applications of Exosomes in Different Types of Diseases: A Review
Current Molecular Medicine Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device through Turbiscan Lab Expert
Medicinal Chemistry Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients
Current Neurovascular Research Nerve Growth Factor in Neurological and Non-Neurological Diseases: Basic Findings and Emerging Pharmacological Prospectives
Current Pharmaceutical Design Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Ebola Virus Altered Innate and Adaptive Immune Response Signalling Pathways: Implications for Novel Therapeutic Approaches
Infectious Disorders - Drug Targets Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Editorial (Thematic Issue: Is The Female Heart Exposed To Cardiovascular Disease?)
Current Medicinal Chemistry γ-Secretase-Regulated Signaling Typified by Notch Signaling in the Immune System
Current Stem Cell Research & Therapy